Read More Pharma Industry News Aspen Pharmacare (JSE: APN) ends FY26 with net cash after R28bn APAC sale Aspen expects continuing-operations normalised earnings per share to rise 19%-24% after a sharp second-half recovery, while the APAC disposal transformed its balance sheet. byVenkateshAugust 29, 2026